Cool it guys!
I am sort of in the middle here I also have been here for almost seven years sold some and bought back a few times but am not a trader and have held most of my shares for the entire time. I have found that most managements are greedy and put their interests before the shareholders that goes without saying. Also I do not doubt that Brad wants a successfull product not just for his pocketboook, what family had not been touched by cancer. Before two years ago I gave Brad poor marks and stick with that but over the last two years I give him a B. He still disappoints like his recent miss on phase III, if he had hit his target he might have stopped this dip in the stock who knows. I fully expect that whatever target he gives for Phase III they will miss it, I take that for granted now. To sum up my feeling on Brad has been like a roller coaster and until recently was moving up.
Anyone going to the annual meeting I have a couple questions if anyone wants to ask them. I have more than a little concern over the pace of enrollment in US trials. The H&N confirmation trial should have been a breeze with the results we had in the UK, the fact that only fourteen patients are taking so long is making me very nervous and may be a factor in our stock price, not sure!